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Abstract 
OBJECTIVE. Diabetes mellitus is associated with an increased risk of cardiovascular disease (CVD) and death. 
Because the prevalence of diabetes is rising worldwide and chronic heart failure (CHF) is becoming increasingly 
common with the aging population, it is timely to examine the impact of diabetes per se on 1-year adverse outcomes 
in patients with CHF. 
RESEARCH DESIGN AND METHODS. We prospectively assessed whether diabetes status independently affected 
the 1-year risk of all-cause and CVD mortality and first hospitalization for worsening heart failure (HF) in a 
multinational cohort of 9,428 outpatients with CHF enrolled in the European Society of Cardiology and Heart Failure 
Association Long-Term Registry. 
RESULTS. Compared with those patients without diabetes, patients with diabetes (n = 3,440, 36.5%) had higher 
cumulative rates of 1-year all-cause death (9.4% vs. 7.2%; adjusted hazard ratio [HR] 1.28; 95% CI 1.07–1.54), CVD 
death (4.8% vs. 3.8%; adjusted HR 1.28; 95% CI 0.99–1.66), and HF hospitalization (13.8% vs. 9.3%; adjusted HR 
1.37; 95% CI 1.17–1.60), all independent of age, sex, BMI, smoking, systolic blood pressure, estimated glomerular 
filtration rate, hemoglobin, HF etiology, left ventricular ejection fraction, hypertension, statin use, and prior stroke or 
chronic obstructive pulmonary disease. Among CHF patients with HbA1c measurements available at baseline (n = 
2,567), there was a significant and independent association between increasing HbA1c levels and the risk of 1-year 
survival outcomes. 
CONCLUSIONS. The presence of diabetes markedly increases the risk of 1-year adverse clinical outcomes in 
outpatients with CHF independent of multiple common risk factors. More effective and personalized treatment for 
diabetes should be considered in this particularly high-risk patient population. 
INTRODUCTION 
The prevalence of type 2 diabetes has steadily increased in many parts of the world and is expected to 
continue increasing as obesity and other clinical risk factors for diabetes become more common (1–3). 
Overt diabetes and prediabetes states are often associated with an increased risk of cardiovascular disease 
(CVD) (4,5), which remains the leading cause of mortality worldwide, despite a striking reduction in age-
adjusted CVD mortality rates over the last 30 years (6). This means that CVD mortality has been delayed 
but not solved. 
 
Chronic heart failure (CHF) is a progressive, complex clinical syndrome of the elderly (7), and the 
prognostic impact of diabetes itself in patients with CHF may be clinically relevant as these two 
pathologic conditions often coexist and share common risk factors and comorbidities that lead to early 
death, including unhealthy lifestyles and multiple cardiometabolic disorders, such as hypertension, 
chronic kidney disease (CKD), dyslipidemia, and hypercoagulability (7). CHF itself also worsens 
systemic insulin resistance and may make diabetes more prevalent with a poorer quality of glycemic 
control. Currently, a large proportion of CVD hospital admissions comprise patients affected by a 
worsening of CHF, a disease often associated with type 2 diabetes and poor short- and long-term survival 
outcomes (7,8). 
 
The relationship between type 2 diabetes and survival outcomes in the context of multimorbidity in 
patients with CHF (e.g., ischemic heart disease, hypertension, and CKD) has been known for more than a 
decade (7–10), but there are very few contemporary, comparative data on the midterm/long-term survival 
outcomes from large European cohorts of ambulatory patients with CHF. In addition, as will be discussed 
in detail below, the observational registries and randomized clinical trials that have explored the 
independent prognostic impact of diabetes on survival outcomes in patients with CHF have reported 
conflicting or inconclusive results, suggesting the need for further studies. Currently, there is continued 
debate on this topic and, therefore, it warrants in-depth investigation. 
  
Thus, in the current study we sought to explore the prognostic impact of diabetes per se on the 1-year 
rates of all-cause death, CVD death, and first hospitalization for worsening heart failure (HF) among 
outpatients with CHF who are enrolled in the General Long-Term Registry of the EURObservational 
Research Programme (EORP) of the European Society of Cardiology (ESC) and the ESC-Heart Failure 
Association (HFA). 
RESEARCH DESIGN AND METHODS 
Study Design 
The principles and procedures of the EORP of the ESC have previously been described (11,12). 
Briefly, the ESC-HFA Heart Failure Long-Term Registry is a prospective, multicenter, observational 
study of patients at 211 cardiology centers in 21 European and Mediterranean countries that are members 
of the ESC. The ESC-HFA endorsed the study, which was conducted by an ad hoc executive committee. 
 
The national cardiology societies of each country agreed to participate in the program and were asked 
to select hospitals of different levels of complexity from which patients could be recruited. The aim was 
to include a broad spectrum of cardiology and/or HF units following outpatients with HF and admitting 
patients with acute, worsening, or de novo HF to develop a network of centers that would be reasonably 
representative of the European reality. The number of participating centers from each country was 
decided according to the number of inhabitants in that country (i.e., 1 center per 2 million people, but no 
more than 25 and no less than 6 per country). To the extent that it was possible, the centers were also 
chosen to fulfill geographical criteria within each country. In this way, the registry included a balanced 
proportion of centers with a range of cardiology facilities. 
 
The EORP Department at the ESC European Heart House was appointed to coordinate the operations 
of the project; to provide support to the committees, national coordinators, and participating centers; and 
to oversee the methodological aspects of the survey. The database was established at the European Heart 
House, according to the requirements defined by the appointed executive committee with the support of 
the EORP Department. 
 
The registry was approved by each local institutional review board according to the rules of each 
participating country. No data were collected before detailed information was provided to the patient and 
signed informed consent had been obtained. 
Patient Population 
From May 2011 to April 2013, all outpatients with CHF who were observed at the clinics and those 
admitted to the hospital for acute HF were included in the registry during the enrollment period (on 1 day 
per week for 12 consecutive months) (11,12). There were no specific exclusion criteria, except for age 
≤18 years. For the clinical diagnosis of HF, we applied the 2012 ESC-HF guidelines, as the registry was 
conducted in the European population (13). As specified above, the participating centers enrolled patients 
in the registry on a 1 day-per-week basis. Therefore, the following patients were entered in our registry: 
1) all outpatients with CHF (n = 9,428) diagnosed according to the clinical judgment of the responsible 
cardiologist at the participating centers; and 2) all inpatients (n = 6,926) admitted to the hospital 
cardiology ward or intensive cardiac care unit for acute HF for whom an intravenous therapy (inotropes, 
vasodilators, or diuretics) was needed. 
  
The 1-year follow-up data concerning the clinical outcomes of all inpatients hospitalized with HF 
have been published previously (12). In the current analysis, we present the 1-year follow-up data from 
the registry concerning the rates of all-cause death, CVD death (i.e., due either to cardiac or vascular 
reasons) and first hospitalization for worsening HF of outpatients with CHF (n = 9,428). No detailed 
information on specific causes of non-CVD mortality was available in the registry. 
The Diagnosis of Diabetes and Other Clinical and Laboratory Data 
Previously known diabetes was defined as self-reported physician-diagnosed diabetes, or use of 
hypoglycemic medications (insulin or oral agents). In the absence of previously known diabetes, the 
diagnosis of new-onset diabetes was based on a fasting plasma glucose level ≥7.0 mmol/L (≥126 mg/dL) 
and/or a hemoglobin A1c (HbA1c) level ≥6.5% (≥48 mmol/mol), respectively. We were unable to 
distinguish between type 1 and type 2 diabetes, although the vast majority of our patients with diabetes 
were likely to have type 2 diabetes. 
 
BMI was calculated by dividing patients’ weight in kilograms by their height in meters squared. 
Blood pressure was measured with a mercury sphygmomanometer at the right upper arm using an 
appropriate cuff size after the patient had been seated quietly for at least 5 min. The presence of 
hypertension was defined as blood pressure values ≥140/90 mmHg or a self-reported history of physician-
diagnosed hypertension. Venous blood samples were drawn in the morning after an overnight fast. Serum 
creatinine, glucose, and HbA1c measurements (which were available in 2,567 patients: 1,603 with diabetes 
and 964 without diabetes) and other biochemical blood measurements were determined using standard 
laboratory procedures. The estimated glomerular filtration rate (eGFR) was estimated by the four-variable 
Modification of Diet in Renal Disease (MDRD) study equation (14). The presence of CKD was defined 
as an eGFRMDRD value of <60 mL/min/1.73 m
2
 (14); measurements of albuminuria or proteinuria were 
not available. Conventional transthoracic echocardiography was used to measure the left ventricular (LV) 
diameter, LV wall thickness, and LV ejection fraction (LVEF) according to international standard criteria. 
Statistical Analysis 
The statistical analyses were performed at the ESC European Heart House. Univariate analysis was 
applied to both continuous and categorical variables. Categorical variables were reported and compared 
using the χ2 test or the Fisher exact test if any expected cell count was <5. For categorical variables with 
more than two possible values, exact P values were estimated according to the Monte Carlo method. 
Continuous variables were reported either as the mean ± SD or as the median (interquartile range). 
Among-group comparisons were made using a nonparametric test (the Kruskal-Wallis test). A 
multivariable Cox regression analysis (Table 2), adjusted for age, sex, systolic blood pressure, eGFRMDRD, 
hemoglobin, BMI, smoking, hypertension status, LVEF, HF etiology, statin use, and history of stroke and 
chronic obstructive pulmonary disease (COPD), was applied to estimate the 1-year risk associated with 
diabetes status in terms of 1-year all-cause death, CVD death, and first hospitalization for worsening HF. 
Interaction terms were also generated between diabetes status and sex for each clinical outcome. Because 
the diabetes × sex interaction term (P > 0.40) was not statistically significant, a sex-pooled multivariable 
regression analysis was used to assess the independence of the association between diabetes status and 
each clinical outcome. The covariates included in these forced-entry Cox multivariable regression models 
were selected as potential confounding factors on the basis of their significance in univariate regression 
analyses or on the basis of their biological plausibility. We also examined the association between 
increasing HbA1c levels at baseline and the risk of 1-year clinical outcomes. For each outcome, a 
restricted cubic-spline Cox regression plot has been realized without adjustment and with adjustment for 
age, sex, systolic blood pressure, eGFRMDRD, HF etiology, LVEF, and hemoglobin values. A two-sided P 
value <0.05 was considered statistically significant. All analyses were performed with SAS statistical 
software version 9.4 (SAS Institute, Inc., Cary, NC). 
  
RESULTS 
As shown in Table 1, the study cohort included 9,428 (71.5% male) outpatients with CHF, largely 
composed of overweight or obese individuals of Caucasian ancestry (∼95%). The prevalence of diabetes 
in the study cohort was high (n = 3,440; 36.5%); 80.9% (n = 2,782) of these patients had previously 
known diabetes (i.e., self-reported history or use of hypoglycemic drugs), whereas the remaining 658 
patients (19.1%) had previously undiagnosed diabetes. Among those patients with previously 
undiagnosed diabetes, 187 had a fasting glucose level ≥200 mg/dL, whereas the remaining 471 patients 
had a fasting glucose level between 126 and 199 mg/dL and/or an HbA1c level ≥6.5% (≥48 mmol/mol). 
Table 1 Baseline demographic, clinical, and biochemical characteristics of outpatients with CHF, enrolled in the ESC-HFA Heart 
Failure Long-Term Registry, stratified by diabetes status 
 
N/N 
Patients with diabetes (n = 
3,440) 
Patients without diabetes (n = 
5,988) 
P value 
     
Male sex (%) 3,440/5,988 74.7 69.7 <0.001 
Age (years) 3,440/5,988 67.1 ± 10.9 63.7 ± 14.4 <0.001 
Caucasian ethnicity (%) 3,300/5,654 95.3 94.3 0.033 
BMI (kg/m2) 3,349/5,755 29.5 ± 5.3 27.3 ± 4.9 <0.001 
BMI ≥30 kg/m2 (%) 3,349/5,755 41.8 25.0 <0.001 
Systolic blood pressure (mmHg) 3,439/5,968 126.5 ± 21.4 123.2 ± 20.6 <0.001 
Diastolic blood pressure (mmHg) 3,433/5,988 73.7 ± 12.2 73.9 ± 12.2 0.572 
Total cholesterol (mg/dL) 2,347/3,611 161.5 ± 78.5 173.1 ± 44.3 <0.001 
Heart rate (bpm) 3,163/5,381 74.3 ± 15.9 72.7 ± 16.4 <0.001 
Diabetes medications (%) 3,368/5,770 71.8 0.0 <0.001 
 Insulin  44.6   
 Oral hypoglycemic drugs only  55.4   
Plasma glucose (mg/dL) 2,645/3,933 143.3 ± 60.4 94.4 ± 12.8 <0.001 
HbA1c (%) 1,603/964 7.3 ± 1.5 5.7 ± 0.4 <0.001 
HbA1c (mmol/mol) 1,603/964 56.1 ± 16 38.6 ± 5 <0.001 
Hypertension (%) 3,390/5,808 75.5 58.1 <0.001 
Current smoking (%) 3,440/5,988 9.2 12.5 <0.001 
Lipid-lowering medications (%) 3,369/5,782 69.3 50.2 <0.001 
Cardiovascular medications (%) 3,312/5,655    
 ACE inhibitors or ARBs  87.6 85.6 0.009 
 β-Blockers  86.0 85.7 0.698 
 Aldosterone antagonists  54.1 54.0 0.901 
 Diuretics  87.0 77.6 <0.001 
 Digitalis  24.0 20.4 <0.001 
 Calcium channel blockers  14.4 9.9 <0.001 
 Antiplatelets or anticoagulants  85.8 74.8 <0.001 
 Nitrates  23.6 15.5 <0.001 
 Amiodarone  14.1 13.8 0.708 
Creatinine (mg/dL) 3,202/5,335 1.2 (0.9–1.5) 1.1 (0.9–1.3) <0.001 
eGFRMDRD (mL/min/1.73 m
2) 3,202/5,335 58.3 (42.1–75.7) 66.3 (50.6–82.7) <0.001 
eGFRMDRD <60 mL/min/1.73 m
2 (%) 3,202/5,335 52.4 39.5 <0.001 
Hemoglobin (g/dL) 2,976/4,906 13.1 ± 1.8 13.5 ± 1.9 <0.001 
NT-proBNP (pg/dL) 1,194/1,970 1,324 (546–3,470) 1,240 (467–3,373) 0.131 
LVEF (%) 2,969/5,099 37.1 ± 13.1 37.9 ± 13.7 0.010 
LVEF >45% (%) 2,969/5,099 22.6 24.7 0.040 
NYHA functional class (%) 3,433/5,970   <0.001 
Table 1 Baseline demographic, clinical, and biochemical characteristics of outpatients with CHF, enrolled in the ESC-HFA Heart 
Failure Long-Term Registry, stratified by diabetes status 
 
N/N 
Patients with diabetes (n = 
3,440) 
Patients without diabetes (n = 
5,988) 
P value 
 Class I  13.5 19.4  
 Class I  57.6 56.1  
 Class III  26.3 22.8  
 Class IV  2.6 1.7  
HF etiology (%) 3,430/5,942   <0.001 
 Ischemic  53.4 36.8  
 Dilatative  23.8 32.3  
 Hypertensive  8.5 8.1  
 Other  14.3 22.7  
Atrial fibrillation (%) 3,440/5,987 39.2 36.5 0.009 
Implantable cardioverter defibrillator 
(%) 
3,429/5,970 16.4 15.3 0.127 
COPD (%) 3,435/5,974 16.6 12.6 <0.001 
Previous stroke (%) 3,436/5,983 10.8 8.5 <0.001 
     
 
Data are presented as the mean ± SD or median (interquartile range), unless otherwise indicated. ARB, angiotensin receptor blocker; 
N/N, number of patients with and without diabetes who had measurements available for each single variable at the study entry; NT-
proBNP, N-terminal of the prohormone brain natriuretic peptide. 
As also shown in Table 1, compared with those patients without diabetes, those with known or 
previously undiagnosed diabetes were older and were more likely to be obese, have hypertension, and be 
treated with antihypertensive drugs (i.e., angiotensin-converting enzyme inhibitors, angiotension receptor 
blockers, diuretic agents, or calcium channel blockers) or “cardiovascular” medications (i.e., digitalis, 
nitrates, antiplatelet drugs, or anticoagulant agents). Additionally, they were less often smokers and had a 
more severe New York Heart Association (NYHA) functional class, lower values of eGFRMDRD and 
hemoglobin, and a higher prevalence of ischemic HF etiology, atrial fibrillation, and a history of stroke or 
COPD. Notably, no significant differences were found in circulating levels of N-terminal of prohormone 
brain natriuretic peptide, which were measured in 3,164 patients; the presence of implantable cardioverter 
defibrillators; and current use of β-blockers or aldosterone antagonists between the two groups of 
patients. 
 
Over the 1-year follow-up period, there were a total of 757 deaths (8.0%), 394 of them due to CVD 
causes, and 1,030 (10.9%) first hospitalizations for worsening HF. 
 
As shown in Fig. 1, patients with diabetes had substantially higher cumulative incidence rates of 1-
year all-cause death (9.4% vs. 7.2%), CVD death (4.8% vs. 3.8%), and first hospitalization for worsening 
HF (13.8% vs. 9.3%) compared with their counterparts without diabetes (P = 0.017 to <0.001 for 
differences between the groups). 
  
 
 
 
Figure 1 One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes 
status at baseline. The figure shows the 1-year rates of all-cause death, CVD death, and first hospitalization for worsening HF in 
3,440 CHF outpatients with diabetes (black bars) and 5,988 CHF outpatients without diabetes (dashed bars) who were enrolled in 
the ESC-HFA Heart Failure Long-Term Registry. 
Table 2 shows the results after adjusting for multiple risk factors regarding the association between 
diabetes status and the risk of 1-year clinical outcomes. Patients with diabetes had an ∼30% increased 
risk of all-cause death (adjusted hazard ratio [HR] 1.28; 95% CI 1.07–1.54) and CVD death (adjusted HR 
1.28; 95% CI 0.99–1.66), and an even higher risk of first hospitalization for worsening HF (adjusted HR 
1.37; 95% CI 1.17–1.60) compared with patients without diabetes. Notably, the 1-year risk associated 
with diabetes comorbid with CHF for each of these clinical outcomes was essentially on the same order as 
that of having a history of stroke or COPD. Other variables that were independently associated with 
poorer clinical outcomes were older age, lower systolic blood pressure, lower eGFRMDRD, lower 
hemoglobin level, lower LVEF, not receiving statins, and prior stroke or COPD. Almost identical results 
were found even when eGFRMDRD was replaced by eGFR estimated by the CKD Epidemiology 
Collaboration equation or when hypertension status was removed from the list of covariates (data not 
shown). 
  
Table 2 Multivariable Cox regression analysis of 1-year adverse clinical outcomes in the cohort of outpatients with CHF 
Variables 
All-cause death  CVD death  HF hospitalization 
HR (95% CI) P value  HR (95% CI) P value  HR (95% CI) P value 
         
Diabetes status (yes vs. no) 1.28 (1.07–1.54) 0.008  1.28 (0.99–1.66] 0.060  1.37 (1.17–1.60) <0.001 
Age (years) 1.03 (1.02–1.03) <0.001  1.03 (1.02–1.04) <0.001  1.01 (1.00–1.02) 0.006 
Sex (male vs. female) 1.41 (1.14–1.75) 0.002  1.32 (0.98–1.78) 0.065  1.18 (0.99–1.41) 0.073 
Systolic blood pressure (mmHg) 0.99 (0.98–0.99) <0.001  0.98 (0.97–0.98) <0.001  0.99 (0.98–0.99) <0.001 
eGFRMDRD (mL/min/1.73 m
2) 0.99 (0.98–0.99) <0.001  0.98 (0.98–0.99) <0.001  0.99 (0.98–0.99) <0.001 
LVEF (%) 0.99 (0.98–0.99) <0.001  0.99 (0.98–1.00) 0.002  0.98 (0.97–0.99) <0.001 
HF etiology (ischemic vs. nonischemic) 1.20 (0.99–1.46) 0.063  1.21 (0.92–1.58) 0.177  0.83 (0.71–0.98) 0.026 
BMI (kg/m2) 0.98 (0.96–1.00) 0.037  0.96 (0.94–0.99) 0.010  1.00 (0.99–1.02) 0.395 
Smoking (yes vs. no) 0.90 (0.67–1.21) 0.470  0.95 (0.64–1.42) 0.816  1.00 (0.79–1.28) 0.989 
Hypertension (yes vs. no) 1.06 (0.86–1.30) 0.585  1.03 (0.79–1.36) 0.809  1.21 (1.01–1.44) 0.036 
Statin use (yes vs. no) 0.77 (0.63–0.93) 0.007  0.69 (0.52–0.90) 0.006  1.00 (0.85–1.18) 0.958 
Previous stroke (yes vs. no) 1.36 (1.06–1.76) 0.016  1.46 (1.03–2.06) 0.033  1.42 (1.15–1.76) 0.001 
Previous COPD (yes vs. no) 1.37 (1.10–1.71) 0.005  1.42 (1.05–1.94) 0.024  1.42 (1.18–1.71) <0.001 
Hemoglobin (g/dL) 0.81 (0.77–0.85) <0.001  0.82 (0.77–0.87) <0.001  0.89 (0.85–0.93) <0.001 
         
 
Cohort sizes: n = 6,463 for regression models with 1-year all-cause or CVD mortality as outcome; n = 6,446 for regression model 
with 1-year HF hospitalization as outcome. The values of HRs and 95% CIs were rounded to the second decimal place. 
Figure 2 shows a restricted cubic-spline Cox regression plot of the unadjusted and adjusted 
associations between increasing HbA1c levels (i.e., the reference category used in the Fig. 2 was an HbA1c 
level of 6.5% [48 mmol/mol]) and the risk of all-cause death, CVD death, and first hospitalization for 
worsening HF among the 2,567 CHF patients with HbA1c measurements at baseline. We found a 
significant association of increasing HbA1c levels with the risk of 1-year survival outcomes, but not with 
HF hospitalization, after adjustment for age, sex, systolic blood pressure, eGFRMDRD, LVEF, HF etiology, 
and hemoglobin values. These results should be interpreted with some caution, given that baseline HbA1c 
measurements were available only in a subgroup of CHF patients. However, we believe that this subgroup 
of 2,567 patients was sufficiently representative of the whole cohort of patients, given that the main 
clinical variables (also including LVEF and HF etiology), and especially the rates of 1-year clinical 
outcomes, were essentially comparable between patients with and without HbA1c measurements available 
at baseline, irrespective of pre-existing diabetes (Supplementary Tables 1 and 2). 
  
 
 
 
Figure 2. Unadjusted and adjusted HRs (±95% CIs, presented with dotted lines) of 1-year all-cause death (panel A [unadjusted HR] 
and panel B [adjusted HR]), CVD death (panel C [unadjusted HR] and panel D [adjusted HR]), and first hospitalization for 
worsening HF (panel E [unadjusted HR] and panel F [adjusted HR]) according to increasing HbA1c levels in a subgroup of 2,567 
CHF patients with HbA1c measurements available at baseline. The reference category used in the figure was an HbA1c level of 6.5% 
(or 48 mmol/mol; on the x-axis, the HbA1c values were dually reported as percentage and mmol/mol). Data are adjusted for age, sex, 
systolic blood pressure, eGFRMDRD, LVEF, HF etiology, and hemoglobin values. 
Finally, we also performed a series of sensitivity analyses (subgroup analyses) to assess the robustness 
of our observations. Supplementary Table 3 shows the unadjusted and adjusted associations between 
patients with preserved LVEF versus those with reduced LVEF at baseline and the risk of 1-year clinical 
outcomes stratified by diabetes status. Supplementary Table 4 shows the unadjusted and adjusted 
associations between those patients with ischemic HF versus those with nonischemic HF etiology and the 
risk of 1-year clinical outcomes stratified by diabetes status. Notably, in both of these sensitivity analyses, 
the rates per 100 patient-years of each clinical outcome were almost always higher in patients with 
diabetes than in those without diabetes, irrespective of HF etiology or LVEF at baseline. Both in patients 
with and without diabetes, there was a significant adjusted association between the presence of baseline 
LVEF ≤45% and increased risk of 1-year survival outcomes (CVD death for patients with diabetes and 
all-cause death for those without diabetes, respectively) and 1-year HF hospitalization. In contrast, no 
significant associations were found between those patients with ischemic versus nonischemic HF at the 
study entry and the risk of 1-year survival outcomes or HF hospitalization after adjusting for potential 
confounders. Finally, as shown in Supplementary Table 5, there were no significant adjusted associations 
between diabetes treatment at baseline and the risk of 1-year clinical outcomes in the subgroup of patients 
with diabetes. However, these results should be interpreted with (some) caution, given the lack of any 
detailed information about the different classes of oral hypoglycemic agents. 
CONCLUSIONS 
In this prospective, observational registry of a large unselected European population of consecutive 
outpatients with CHF (n = 9,428), we observed the following: 1) known or previously undiagnosed 
diabetes was highly prevalent among ambulatory patients with CHF (occurring in up to 37% of these 
patients); 2) CHF patients with known or previously undiagnosed diabetes had substantially higher 1-year 
rates of all-cause death, CVD death, and first hospitalization for worsening HF than those without 
diabetes; 3) the association between diabetes and 1-year clinical outcomes remained statistically 
significant even after adjustment for multiple established risk factors and potential confounding variables 
(including also hypertension, eGFRMDRD, hemoglobin, HF etiology, and LVEF); and 4) there was a 
significant and independent association between increasing HbA1c levels and elevated risk of 1-year 
survival outcomes in the subset of 2,567 CHF patients with available HbA1c measurements at baseline. 
 
Our findings provide a contemporary picture of midterm (1-year) adverse clinical outcomes of a large 
European cohort of CHF outpatients with and without diabetes, outside the context of randomized clinical 
trials. Additionally, our findings also shed light on the previously reported discrepant results (as discussed 
below) regarding the independent prognostic impact of diabetes on 1-year clinical outcomes among 
outpatients with CHF. To date, despite the extremely high prevalence of diabetes among patients with 
acute or chronic HF (ranging from 30% to 50%) (10), the association between diabetes and HF often 
remains under-recognized by clinicians, and there are inconclusive or conflicting results regarding the 
independent prognostic impact of diabetes on the risk of mortality and hospitalization, both in the short 
term and in the midterm, among ambulatory patients with CHF. 
 
Collectively, our data confirm and expand previous findings from observational registries and 
randomized clinical trials of patients with CHF supporting the existence of a significant and independent 
association between diabetes status and risk of adverse clinical outcomes (15–19). For instance, the 
Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) trial, 
involving 7,599 patients with symptomatic CHF observed for a median period of ∼3 years, reported that 
pre-existing diabetes was a powerful predictor of all-cause death and of a composite of cardiovascular 
death or HF hospitalization (15). A prospective analysis of the Norwegian Heart Failure Registry, 
involving ∼4,000 patients with CHF (mean follow-up time of 13 months), also highlighted the 
independent prognostic role of diabetes in the risk of all-cause mortality (16). Similar results were also 
found in the Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca (GISSI-HF) 
trial (mean follow-up time of 3.9 years) (17). A recent post hoc analysis of the Prospective Comparison of 
ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure 
(PARADIGM-HF) trial found that the presence of diabetes was independently associated with an 
increased risk of the composite of cardiovascular death or HF hospitalization in 8,399 CHF patients with 
LVEF <35%, who were randomly assigned to receive sacubitril/valsartan treatment or enalapril and 
followed up for 3 years (18). Finally, in the Swedish Heart Failure Registry, involving 35,163 patients 
with HF, diabetes status independently predicted mortality risk, regardless of the coexistence of ischemic 
heart disease (19). 
 
However, our findings also contrast with those from other previously published large clinical trials, 
including the Studies Of Left Ventricular Dysfunction (SOLVD) Prevention and Treatment trial, the 
Digitalis Investigation Group (DIG) trial, and the Beta-Blocker Evaluation of Survival trial (BEST) (20–
22), which have suggested that the prognostic impact of diabetes per se on survival outcomes, if any, 
might be confined only to patients with ischemic HF. Moreover, Kosiborod et al. (23) did not find any 
significant relationship between the presence of pre-existing diabetes (or elevated blood glucose levels at 
hospital admission) and the risk of 30-day or 1-year mortality in a nationally representative sample of 
U.S. elderly patients hospitalized with HF. Finally, in the Surgical Treatment for Ischemic Heart Failure 
(STICH) trial the presence of diabetes was not independently associated with the 5-year risk of all-cause 
and CVD death in a sample of 1,212 patients with ischemic HF (24). 
 
More recently, the MAGGIC (Meta-analysis Global Group in Chronic Heart Failure) meta-analysis 
(25), which included individual data on nearly 40,000 HF patients with preserved or reduced LVEF at 
baseline from 30 cohort studies (6 of which were clinical trials) has reported that pre-existing diabetes 
independently predicted the risk of all-cause death during a median follow-up period of 2.5 years. In this 
meta-analysis, other independent predictors of mortality were older age, lower LVEF, higher NYHA 
functional class, higher serum creatinine level, lower systolic blood pressure, lower BMI, history of 
COPD, and not being prescribed β-blockers, ACE inhibitors, or angiotensin receptor blockers (25). 
 
Similar to the results of the CHARM trial (26) and the PARADIGM-HF trial (18), our findings also 
show that there was a significant relationship between increasing HbA1c levels and the risk of 1-year 
survival outcomes (but not 1-year HF hospitalizations) in the subset of CHF patients with and without 
diabetes with HbA1c measurement available at baseline. 
 
The major strengths of our study are intrinsic to the design of the ESC-HFA Heart Failure Long-Term 
Registry which is one of the largest, multinational and nationally representative systematic collections of 
contemporary European patients with acute and chronic HF. The sample size of our registry provides an 
adequate statistical power to keep the possible occurrence of both type I and type II errors to a minimum. 
Thus, we believe that the added value of our registry to the existing literature is that it provides solid and 
updated data regarding 1-year survival rates in a large unselected cohort of CHF outpatients followed by 
cardiologists, thus providing a picture of European patients who were not included in randomized clinical 
trials but were currently being treated in general cardiology clinical practice. In addition, our registry also 
provides clear evidence of the independent prognostic impact of diabetes on risk of 1-year survival 
outcomes, independent of coexisting clinical risk factors. Finally, in our registry, thorough sensitivity 
analyses that accounted for a reasonably large number of established risk factors were also possible 
because of the availability of systematically collected clinical data, laboratory measures, and instrumental 
data (including echocardiographic functional measures, i.e., LVEF) for a large number of patients. 
 
However, some important limitations of our registry should also be mentioned, as follows: 1) despite 
the methodological desirability of consecutive enrollment, consecutive enrollment cannot be fully proven 
to have occurred in our cohort of CHF outpatients, although local audits were performed to verify the 
quality of data and the consecutiveness of enrollment; 2) the identification of diabetes subtypes was not 
feasible, although patients with diabetes subtypes other than type 2 probably represented a minimal 
proportion of our patients; 3) all clinical outcomes were physician reported but were not adjudicated by a 
blinded end point committee; and 4) information about the duration of diabetes, the use of different 
classes of oral hypoglycemic agents, and the extracardiac causes of mortality as well as follow-up data on 
HbA1c measurements were not available. 
 
In conclusion, our contemporary results from the ESC-HFA Heart Failure Long-Term Registry show 
that the presence of known or previously undiagnosed diabetes is associated with a substantially increased 
risk of 1-year all-cause death, CVD death, and first hospitalization for worsening HF in a large cohort of 
outpatients with CHF. Notably, this association remains statistically significant even after adjusting for 
established risk factors and potential confounding variables. These findings are relevant to 
cardiologists/practicing physicians in routine clinical practice because the early identification of an 
ambulatory patient with CHF and diabetes might translate into a patient-tailored, team-based clinical 
approach, including the timely recognition of multimorbidity, earlier referral to the clinical diabetologists, 
and implementation of closer follow-up schedules. In the context of the prospective global estimates for a 
longer life expectancy, and in an era in which there is increasing emphasis on long-term disease 
management to contain health care costs, these findings further highlight the prognostic value of diabetes 
comorbid with CHF and the need for further therapies that can improve survival outcomes in this 
particularly high-risk patient population. 
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